Journal
ANTIBIOTICS-BASEL
Volume 11, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/antibiotics11020133
Keywords
tuberculosis; drug resistance; ethionamide; isoniazid; perchlozone
Categories
Funding
- Russian Foundation for Basic Research [20-01500463]
Ask authors/readers for more resources
Ethionamide susceptibility testing methods are imperfectly correlated in drug-resistant tuberculosis, and a significant proportion of resistant TB cases are susceptible to ethionamide treatment.
Background: Ethionamide and prothionamide are now included in group C of the WHO recommended drugs for the treatment of tuberculosis resistant to rifampicin and multidrug-resistant tuberculosis. The clinical relevance of ethionamide and prothionamide has increased with the wide spread of resistant tuberculosis. Methods: We retrospectively analyzed 349 clinical isolates obtained between 2016 and 2020. The susceptibility to ethionamide was tested using both the Bactec(TM) MGIT(TM) 960 system and the Sensititre(TM) MYCOTB plate. Results: The MIC of ethionamide increases with the total resistance of the isolates in a row from susceptible to XDR strains. A significant part of the isolates have a MIC below the breakpoint: 25%, 36%, and 50% for XDR, pre-XDR, and MDR strains. Sensitivity and specificity of detection of mutations were 96% and 86% using MGIT resistance as a reference. Conclusions: Phenotypic methods for testing ethionamide are imperfectly correlated, and the isolates with MIC of 5 mg/L have the intermediate resistance. A significant proportion of resistant TB cases are susceptible and eligible for ethionamide treatment. Resistance could be explained using only analysis of loci ethA, P-fabG1, and inhA for most isolates in the Moscow region. The promoter mutation P-fabG1 c(-15)t predicts resistance to ethionamide with high specificity but low sensitivity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available